 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
OraPharma, Inc. 732 Louis Dr. Warminster, PA 18974 Phone: 215-956-2200 Fax: 215-443-9531 orapharma.com OraPharma wants to save your toothy grin. The development-stage company's Minocycline Periodontal Therapeutic System (MPTS) is aimed at wiping out periodontitis, a leading cause of adult tooth loss. Using a polymer microsphere delivery system licensed from American Home Products subsidiary American Cyanamid, MPTS delivers a sustained dose of antibiotic to an infection site after plaque removal. The company is also developing a treatment for oral mucositis (a condition that occurs frequently in patients receiving chemotherapy or radiation therapy) and a therapy for bone and soft-tissue regeneration. The company is owned by a group of investment firms that includes Oak Investment Partners and Canaan Partners. Top Competitors Atrix Labs | CollaGenex Pharmaceuticals | Perio Products IPO Information Filing Date: Dec 30, 1999 Expected IPO Date: Mar 6, 2000 Proposed offer price: $15.00 to $17.00 Shares offered (mil.): 4.0 Offering amount (mil.): $64.0 Post-offering shares (mil.): 12.6 Underwriters: Robertson, Stephens & Company; U.S. Bancorp Piper Jaffray; Gerard Klauer Mattison & Co., Inc. | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2026 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |